Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorAndré, Fabrice
dc.contributor.authorBustillos, A.
dc.contributor.authorFear, S.
dc.contributor.authorGanta, S.
dc.contributor.authorBlay, Jean-Yves
dc.date.accessioned2022-08-10T06:26:17Z
dc.date.available2022-08-10T06:26:17Z
dc.date.issued2022-04
dc.identifier.citationTabernero J, Andre F, Blay JY, Bustillos A, Fear S, Ganta S, et al. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. ESMO Open. 2022 Apr;7(2):100419.
dc.identifier.issn2059-7029
dc.identifier.urihttps://hdl.handle.net/11351/7976
dc.descriptionInhibidor del punt de control PD-L1; Atezolizumab; Tumors sòlids
dc.description.sponsorshipThis study was supported by F. Hoffmann-La Roche (no grant number) who provided financial support for the conduct of study and were involved in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. They also funded assistance with manuscript writing by a professional medical writer.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesESMO Open;7(2)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Tractament
dc.subjectAnticossos monoclonals
dc.subject.meshNeoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.titlePhase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.esmoop.2022.100419
dc.subject.decsneoplasias
dc.subject.decs/farmacoterapia
dc.subject.decsanticuerpos monoclonales humanizados
dc.relation.publishversionhttps://doi.org/10.1016/j.esmoop.2022.100419
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Spain. [Andre F] Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. [Blay JY] Centre Léon Bérard, Lyon, France. [Bustillos A, Fear S] Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland. [Ganta S] Product Development Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland
dc.identifier.pmid35305400
dc.identifier.wos000797892800010
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple